

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



思路迪医药
3D Medicines
3D Medicines Inc.
思路迪医药股份有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1244)

CHANGE OF CHIEF FINANCIAL OFFICER

This announcement is made by 3D Medicines Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that (i) Ms. Zhang Jing (“**Ms. Zhang**”) has tendered her resignation as the chief financial officer (“**Chief Financial Officer**”) of the Company; and (ii) Mr. Lu Xiaohao (“**Mr. Lu**”) has been appointed as the Chief Financial Officer, effective from the date of this announcement.

Ms. Zhang has confirmed that she has no disagreement with the Board and there are no matters relating to her resignation as the Chief Financial Officer that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company.

The biographical details of Mr. Lu are set out below:

Mr. Lu, 39 years old, possesses nearly 18 years of experience in capital operations and financial management, including over 10 years of investment banking experience. He has a deep understanding and extensive practical experience in both domestic and international capital market operations. From September 2008 to January 2012, he worked at Pricewaterhouse Coopers (PwC), Deloitte Touche Tohmatsu (Deloitte) and Greater China division of GlaxoSmithKline (GSK), engaged in audit assurance, risk advisory, and related services. From February 2012 to June 2023, he served at three securities companies (including China International Capital Corporation Limited), focusing on domestic and international investment banking business. From June 2023 to August 2025, he served as the Chief Financial Officer at Wuhan Vickor Medical Technology Co., Ltd. and Hunan Hengchang Pharmaceutical Group Co., Ltd., respectively.

Mr. Lu holds a Master’s degree in Economics from Fudan University. He is a non-practicing member of the Chinese Institute of Certified Public Accountants and was previously qualified as a sponsor representative in China. Furthermore, Mr. Lu holds Type 1, Type 4, and Type 6 licenses issued by the Securities and Futures Commission of Hong Kong. He is also a Certified Internal Auditor and possesses the Chinese Securities Industry Practitioner qualification.

The Board would like to express its sincere gratitude and appreciation to Ms. Zhang for her valuable contribution and services made to the Company during her tenure of service as chief financial officer and also express its warmest welcome to Mr. Lu on his appointment.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, January 12, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Jinqiao, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.